or Try an Advanced Search...

    Technical Analysis for RNAZ - TransCode Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 1.13 10.78% 0.11
    RNAZ closed down 12.07 percent on Wednesday, May 8, 2024, on 3.14 times normal volume.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Up
    Historical RNAZ trend table...
    Date Alert Name Type % Chg
    Jack-in-the-Box Bullish Bullish Swing Setup 10.78%
    Volume Surge Other 10.78%
    Parabolic Rise Strength 10.78%
    Upper Bollinger Band Walk Strength 10.78%
    Inside Day Range Contraction 10.78%
    Wide Bands Range Expansion 10.78%
    Above Upper BB Strength 10.78%
    Upper Bollinger Band Touch Strength 10.78%
    Gapped Down Weakness 10.78%
    180 Bullish Setup Bullish Swing Setup -2.59%
    Older End-of-Day Signals for RNAZ ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout 24 minutes ago
    Jack-in-the-Box Bullish Entry 24 minutes ago
    Rose Above Previous Day's High 24 minutes ago
    2x Volume Pace 24 minutes ago
    3x Volume Pace 24 minutes ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    RNAZ Chart by TradingView
    Basic chart:

    Profile

    TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs for the treatment of metastatic diseases. The company's lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. Its products in discovery and preclinical stage include MicroRNA-10b, TTX-siPDL1, TTX-siLIN28b, and TTX-RIGA, which focuses on treating various cancers. The company was incorporated in 2016 and is based in Boston, Massachusetts
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Preclinical Stage Product Metastatic Cancer

    Is RNAZ a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 15 TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
    Apr 3 TransCode Therapeutics reports FY results
    Apr 3 TransCode Therapeutics Reports 2023 Results; Provides Business Update
    Mar 28 TransCode Therapeutics appoints Vlock as chief medical officer
    Mar 28 TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
    Mar 11 TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
    Mar 6 TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
    Feb 20 TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
    Jan 31 Transcode Therapeutics regains compliance with Nasdaq listing rules
    Jan 31 Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
    See more RNAZ news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 309.6
    52 Week Low 0.42
    Average Volume 652,549
    200-Day Moving Average 18.34
    50-Day Moving Average 0.66
    20-Day Moving Average 0.63
    10-Day Moving Average 0.74
    Average True Range 0.12
    RSI (14) 69.97
    ADX 46.93
    +DI 45.05
    -DI 7.84
    Chandelier Exit (Long, 3 ATRs) 0.84
    Chandelier Exit (Short, 3 ATRs) 0.78
    Upper Bollinger Bands 1.00
    Lower Bollinger Band 0.25
    Percent B (%b) 1.02
    BandWidth 119.20
    MACD Line 0.07
    MACD Signal Line 0.00
    MACD Histogram 0.0715
    Fundamentals Value
    Market Cap 1.08 Million
    Num Shares 1.06 Million
    EPS -652.00
    Price-to-Earnings (P/E) Ratio 0.00
    Price-to-Sales 0.00
    Price-to-Book 0.16
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.29
    Resistance 3 (R3) 1.29 1.19 1.25
    Resistance 2 (R2) 1.19 1.12 1.20 1.23
    Resistance 1 (R1) 1.11 1.08 1.06 1.11 1.21
    Pivot Point 1.01 1.01 0.99 1.02 1.01
    Support 1 (S1) 0.93 0.94 0.88 0.93 0.83
    Support 2 (S2) 0.83 0.90 0.84 0.81
    Support 3 (S3) 0.75 0.83 0.80
    Support 4 (S4) 0.75